TFRC and glioblastoma: HFn enables targeted delivery to GBM via TfR1. Regorafenib halts autophagy, inducing cell death. Cu2+ enhances drug encapsulation and triggers cuproptosis, augmenting regorafenib's efficacy against GBM.